We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CORMAY

Cormay develops and manufactures diagnostic reagents and laboratory equipment, including hematology analyzers and cli... read more Featured Products: More products

Download Mobile App





Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

Cormay Diagnostics (Warsaw, Poland) is participating in this year’s edition of MEDICA, where the company is presenting its range of high quality diagnostic reagents and advanced laboratory analyzers. More...

At MEDICA 2022, Cormay is showcasing the MYTHIC 70, a true 5+DIFF hematology analyzer that delivers 29 parameters in less than 60 seconds. Its superior technology ensures reliability and multi-patented solution with unmatchable cost savings. It features walk away function and allows loading of 50 samples for improving laboratory efficiency. Alongside the MYTHIC 70, Cormay is exhibiting the MYTHIC 3CRP, a 3 DIFF hematology analyzer that offers a two-in-one solution. The MYTHIC 3CRP analyzer is designed to analyze whole blood samples, including measurement of blood cell count, hemoglobin concentration, CRP concentration and 3-part leukocytes differentiation.

In addition to its range of hematology analyzers, Cormay is also highlighting its portfolio of chemistry analyzers, including the ACCENT M320 and ACCENT S120. The ACCENT M320 and ACCENT S120 are computer-controlled, fully-automated chemistry analyzers for in-vitro diagnostic use in clinical laboratories to measure activity or concentration of clinical chemistry parameters in serum, plasma, urine and cerebrospinal fluid samples. Together with the highest quality dedicated reagent line, calibrators and controls, they provide a complete solution suitable for small to mid-size laboratories.

Among its urine analyzers being showcased by Cormay at MEDICA 2022 are the Uri-Tex and URI-TEX 300 semi-automatic urine chemistry analyzers. Designed to be used with Cormay urinalysis strips, the intelligent Uri-Tex image analyzer locates the strip and the pads, reads the color data, and based on these, determines the parameter values. Its intuitive device operation makes analysis easy and allows for fast determination of multiple chemical compounds in urine. Similarly, the Uri-Tex 300 semiautomatic urine chemistry analyzer is also designed to be used with Cormay urinalysis strips and determines the multiple parameters values in urine in less than a minute. The operator is only required to dip the strips into the samples and place them on the strips loading plate which allows for a maximum of 10 strips to be loaded at one time.

Related Links:
Cormay Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.